132 filings
Page 5 of 7
6-K
llo7c9k10lb0m
16 Aug 21
Current report (foreign)
8:17am
S-8
kjs oo198vv35
16 Jul 21
Registration of securities for employees
4:31pm
6-K
cqnuiiuqra0ln w1s5v
13 May 21
PAINREFORM LTD. Condensed UNAUDITED FINANCIAL STATEMENTS
9:18am
EFFECT
xi16hnxns99vvq
12 Apr 21
Notice of effectiveness
12:15am
424B3
bfwm3
9 Apr 21
Prospectus supplement
4:36pm
CORRESP
scgtp lnr5bl124fsk
8 Apr 21
Correspondence with SEC
12:00am
UPLOAD
8v2whj7w5igj pup
6 Apr 21
Letter from SEC
12:00am
F-1
bziuq3u59skuf2mhdd70
1 Apr 21
Registration statement (foreign)
5:29pm
EFFECT
n6a8yh1
24 Mar 21
Notice of effectiveness
12:15am
POS AM
o766be4ymiqry5
22 Mar 21
Prospectus update (post-effective amendment)
4:15pm
D
8fjlki ju86
19 Mar 21
$6M in equity / options / securities to be acquired, sold $6M, 3 investors
4:15pm
6-K
77x 9b1gah
18 Mar 21
PainReform Provides Year-End Business Update and Reports Progress Towards
10:36am
20-F
h7gita lesk
18 Mar 21
Annual report (foreign)
9:03am
6-K
ows39spptc
9 Mar 21
PainReform Announces $6.0 Million Private Placement
4:15pm
6-K
tijlzc
1 Mar 21
Report of Foreign Private Issuer
7:00am
6-K
cimwd
23 Feb 21
Report of Foreign Private Issuer
4:30pm
6-K
rgotvppz85mncxbl4yw
19 Jan 21
Extraordinary General Meeting of Shareholders
4:35pm
6-K
6hur lzv6tn8dtbkdo7t
6 Jan 21
PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations
9:00am
6-K
n1lx uhsx69po1iwu
5 Jan 21
Investor Presentation January 2021
4:15pm
6-K
vcdga5
4 Jan 21
PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110
4:16pm